Cargando…

Utility of CHROMagar™ Candida Plus for presumptive identification of Candida auris from surveillance samples

Candida auris is a nosocomial fungal pathogen of prime importance due to its global emergence and rapid spread in healthcare facilities worldwide. One important concern is that routine, conventional methods fail to identify C. auris. While molecular and protein-based assays accurately detect/identif...

Descripción completa

Detalles Bibliográficos
Autores principales: Marathe, Anuradha, Zhu, YanChun, Chaturvedi, Vishnu, Chaturvedi, Sudha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9647746/
https://www.ncbi.nlm.nih.gov/pubmed/36355325
http://dx.doi.org/10.1007/s11046-022-00656-3
_version_ 1784827441310597120
author Marathe, Anuradha
Zhu, YanChun
Chaturvedi, Vishnu
Chaturvedi, Sudha
author_facet Marathe, Anuradha
Zhu, YanChun
Chaturvedi, Vishnu
Chaturvedi, Sudha
author_sort Marathe, Anuradha
collection PubMed
description Candida auris is a nosocomial fungal pathogen of prime importance due to its global emergence and rapid spread in healthcare facilities worldwide. One important concern is that routine, conventional methods fail to identify C. auris. While molecular and protein-based assays accurately detect/identify C. auris, these methods are time-consuming, expensive, and require expertise. Therefore, the objective of the present study was to assess the potential use of a novel chromogenic medium, CHROMagar™ Candida Plus, as an economical alternative to expensive and laborious diagnostic tests. We compared CHROMagar™ Candida Plus with the standard enrichment (salt Sabouraud Dulcitol broth) medium to test the recovery efficiency of C. auris from surveillance samples. We also tested CHROMagar™ Candida Plus for its ability to distinguish C. auris from other yeast species. One hundred surveillance samples were cultured on CHROMagar™ Candida Plus and Dulcitol broth and incubated at 37 °C and 40 °C, respectively. Additionally, 32 Candida and yeast species were cultured on CHROMagar™ Candida Plus at 37 °C for three days to rule out any close resemblance to C. auris. Of 100 surveillance samples tested, 69 yielded presumptive positive C. auris exhibiting creamy pink colonies with a blue halo on CHROMagar™ Candida Plus within three days of incubation, and MALDI-TOF MS confirmed all by day 4. On the other hand, 69 of 100 surveillance samples yielded turbidity in Dulcitol broth by days 3–14 with final MALDI identification by days 5 to 17. Both media failed to identify one sample each, resulting in assay sensitivity and specificity of 99% and 97%, respectively. Of Candida and yeast species tested, 75–80% of C. metapsilosis and C. orthospilosis were misidentified as C. auris. However, previous studies indicated that these species are rarely detected in surveillance screening of C. auris. Naganishia diffluens also resembled C. auris, although it required different temperature growth (30 °C). In conclusion, CHROMagar™ Candida Plus provides rapid presumptive identification of C. auris. It would be another valuable tool in surveillance efforts to control the spread of C. auris in healthcare.
format Online
Article
Text
id pubmed-9647746
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-96477462022-11-14 Utility of CHROMagar™ Candida Plus for presumptive identification of Candida auris from surveillance samples Marathe, Anuradha Zhu, YanChun Chaturvedi, Vishnu Chaturvedi, Sudha Mycopathologia Short Communication Candida auris is a nosocomial fungal pathogen of prime importance due to its global emergence and rapid spread in healthcare facilities worldwide. One important concern is that routine, conventional methods fail to identify C. auris. While molecular and protein-based assays accurately detect/identify C. auris, these methods are time-consuming, expensive, and require expertise. Therefore, the objective of the present study was to assess the potential use of a novel chromogenic medium, CHROMagar™ Candida Plus, as an economical alternative to expensive and laborious diagnostic tests. We compared CHROMagar™ Candida Plus with the standard enrichment (salt Sabouraud Dulcitol broth) medium to test the recovery efficiency of C. auris from surveillance samples. We also tested CHROMagar™ Candida Plus for its ability to distinguish C. auris from other yeast species. One hundred surveillance samples were cultured on CHROMagar™ Candida Plus and Dulcitol broth and incubated at 37 °C and 40 °C, respectively. Additionally, 32 Candida and yeast species were cultured on CHROMagar™ Candida Plus at 37 °C for three days to rule out any close resemblance to C. auris. Of 100 surveillance samples tested, 69 yielded presumptive positive C. auris exhibiting creamy pink colonies with a blue halo on CHROMagar™ Candida Plus within three days of incubation, and MALDI-TOF MS confirmed all by day 4. On the other hand, 69 of 100 surveillance samples yielded turbidity in Dulcitol broth by days 3–14 with final MALDI identification by days 5 to 17. Both media failed to identify one sample each, resulting in assay sensitivity and specificity of 99% and 97%, respectively. Of Candida and yeast species tested, 75–80% of C. metapsilosis and C. orthospilosis were misidentified as C. auris. However, previous studies indicated that these species are rarely detected in surveillance screening of C. auris. Naganishia diffluens also resembled C. auris, although it required different temperature growth (30 °C). In conclusion, CHROMagar™ Candida Plus provides rapid presumptive identification of C. auris. It would be another valuable tool in surveillance efforts to control the spread of C. auris in healthcare. Springer Netherlands 2022-11-10 2022 /pmc/articles/PMC9647746/ /pubmed/36355325 http://dx.doi.org/10.1007/s11046-022-00656-3 Text en © This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Short Communication
Marathe, Anuradha
Zhu, YanChun
Chaturvedi, Vishnu
Chaturvedi, Sudha
Utility of CHROMagar™ Candida Plus for presumptive identification of Candida auris from surveillance samples
title Utility of CHROMagar™ Candida Plus for presumptive identification of Candida auris from surveillance samples
title_full Utility of CHROMagar™ Candida Plus for presumptive identification of Candida auris from surveillance samples
title_fullStr Utility of CHROMagar™ Candida Plus for presumptive identification of Candida auris from surveillance samples
title_full_unstemmed Utility of CHROMagar™ Candida Plus for presumptive identification of Candida auris from surveillance samples
title_short Utility of CHROMagar™ Candida Plus for presumptive identification of Candida auris from surveillance samples
title_sort utility of chromagar™ candida plus for presumptive identification of candida auris from surveillance samples
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9647746/
https://www.ncbi.nlm.nih.gov/pubmed/36355325
http://dx.doi.org/10.1007/s11046-022-00656-3
work_keys_str_mv AT maratheanuradha utilityofchromagarcandidaplusforpresumptiveidentificationofcandidaaurisfromsurveillancesamples
AT zhuyanchun utilityofchromagarcandidaplusforpresumptiveidentificationofcandidaaurisfromsurveillancesamples
AT chaturvedivishnu utilityofchromagarcandidaplusforpresumptiveidentificationofcandidaaurisfromsurveillancesamples
AT chaturvedisudha utilityofchromagarcandidaplusforpresumptiveidentificationofcandidaaurisfromsurveillancesamples